Thein, Swee Lay
- National Heart, Lung, and Blood Institute (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #751
- Sustained Excellence
- Top 5% Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2017 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$4.9M
Full award amounts, FY2023
Award Records
5
Records listing this PI
Award-Linked Rank
#751
By linked amount among FY2023 PIs
Earliest Year Loaded
2017
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Thein, Swee Lay as a PI. Multi-PI records show the full award amount for context.
- 1ZIAHL006266-03ZIAContact PIEvaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease$1.5Maward amount
- 1ZIAHL006233-07ZIAContact PIStudies of the Natural History of Sickle Cell Disease$986.8Kaward amount
- 1ZIAHL006240-05ZIAContact PIGenotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$986.8Kaward amount
- 1ZIAHL006283-01ZIAContact PIExploring Near Infrared Spectroscopy (NIRS) technologies for assessment of muscle physiology, tissue oxygenation, and blood flow in patients with Sickle Cell Disease (SCD$986.8Kaward amount
- 1ZIAHL006239-05ZIAContact PIA Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$493.4Kaward amount
Award organization
Organizations that administered FY2023 awards listing Thein, Swee Lay as a PI.
FY2023 award administered by National Heart, Lung, and Blood Institute ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2017First NIH AwardNational Heart, Lung, and Blood Institute
- 2017$500K Cumulative Funding
- 2017$1M Cumulative Funding
- 2017$2M Cumulative Funding
- 2017Entered Top 50% NationallyRanked #847
- 2017Entered Top 25% NationallyRanked #847
- 2017Entered Top 10% NationallyRanked #847
- 2017Entered Top 5% NationallyRanked #847
- 2018$5M Cumulative Funding
- 2019$10M Cumulative Funding
- 2023$25M Cumulative Funding